# Highlights of This Issue

## SPECIAL FEATURES

### CCR Translations

- **Heading in a New Direction: Drug Permeability in Breast Cancer Brain Metastasis**
  - George W. Sledge, Jr.
  - See article p. 5664

### CCR New Strategies

- **New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies**
  - Kieron Dunleavy, Richard L. Piekacz, Jasmine Zain, John E. Janik, Wyndham H. Wilson, Owen A. O’Connor, and Susan E. Bates

### Molecular Pathways

- **The Molecular Basis of Lmo2-Induced T-Cell Acute Lymphoblastic Leukemia**
  - David J. Curtis and Matthew P. McCormack

- **Targeting Hypoxic Cells through the DNA Damage Response**
  - Monica Olcina, Philip S. Lecane, and Ester M. Hammond

### CANCER THERAPY: PRECLINICAL

- **Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer**
  - Paul R. Lockman, Rajender K. Mittapalli, Kunal S. Taskar, Vinay Rudraraju, Brunilde Gril, Kaci A. Bohn, Chris E. Adkins, Amanda Roberts, Helen R. Thorshieim, Julie A. Gaasch, Suyun Huang, Diane Palmieri, Patricia S. Steeg, and Quentin R. Smith
  - See commentary p. 5605

- **Quercetin Induces Tumor-Selective Apoptosis through Downregulation of Mcl-1 and Activation of Bax**
  - Senping Cheng, Ning Gao, Zhao Zhang, Gang Chen, Amit Budhraja, Zunji Ke, Young-ok Son, Xin Wang, Jia Luo, and Xianglin Shi

### HUMAN CANCER BIOLOGY

- **Benign Mesenchymal Stromal Cells in Human Sarcomas**
Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma


Highly Purified Eicosapentaenoic Acid as Free Fatty Acids Strongly Suppresses Polyps in ApcMin/+ Mice

Lucia Fini, Giulia Piazzi, Claudio Ceccarelli, Yahya Daoud, Andrea Belluzzi, Alessandra Munarini, Giulia Graziani, Vincenzo Fogliano, Michael Selgrad, Melissa García, Antonio Gasbarrini, Robert M. Genta, C. Richard Boland, and Luigi Ricciardiello

Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles


Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses

Ling-Yuan Kong, Adam S. Wu, Tiffany Doucette, Jun-Wei, Waldemar Priebe, Gregory N. Fuller, Wei Qiao, Raymond Sawaya, Ganesh Rao, and Amy B. Heimberger

TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors

Dominic Stadel, Andrea Mohr, Caroline Ref, Marion MacFarlane, Shaoxiao Zhou, Robin Humphreys, Max Bachem, Gerry Cohen, Peter Möller, Ralf M. Zwacka, Klaus-Michael Debatin, and Simone Fulda

Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts

Wei-meng Zhao, Lihong Wang, Hangil Park, Sophie Chhim, Melanie Tanphanich, Masakazu Yashiro, and K. Jin Kim

Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer

Yuqi Guo, Jeffrey Nemeth, Colin O’Brien, Michiro Susa, Xianzhe Liu, Zhan Zhang, Edwin Choy, Henry Mankin, Francis Hornick, and Zhenfeng Duan

CEBPĐ Reverses RB/E2F1-Mediated Gene Repression and Participates in HMDB-Induced Apoptosis of Cancer Cells

Yen-Chun Pan, Chien-Feng Li, Chiung-Yuan Ko, Min-Hsiung Pan, Pei-Jung Chen, Joseph T. Tseng, Wen-Chun Wu, Wen-Chang Chang, A-Mei Huang, Esra Sterneck, and Ju-Ming Wang

Dietary Curcumin Attenuates Glioma Growth in a Syngeneic Mouse Model by Inhibition of the JAK1,2/STAT3 Signaling Pathway

Jakob Weissenberger, Maike Priester, Christian Berneuther, Stefanie Rakel, Markus Glatzel, Volker Seifert, and Donat Kögel

DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer

Brian M. Alexander, Kam Sprott, D. Allan Farrow, Xiaozhe Wang, Alan D. D’Andrea, Stuart J. Schnitt, Laura C. Collins, David T. Weaver, and Judy E. Garber

High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy

Steven C.H. Kao, Nick Pavlakis, Rozelle Harvie, Janette L. Vardy, Michael J. Boyer, Nico van Zandwijk, and Stephen J. Clarke

Expression of Snail in Upper Urinary Tract Urothelial Carcinoma: Prognostic Significance and Implications for Tumor Invasion

Takeshi Kosaka, Eiji Kikuchi, Shuji Mikami, Akira Miyajima, Suguru Shirotake, Masaru Ishida, Yasunori Okada, and Mototsugu Oya
Inflammatory and MicroRNA Gene Expression as Prognostic Classifier of Barrett’s Associated Esophageal Adenocarcinoma
Giang Huong Nguyen, Aaron J. Schetter, David B. Chou, Elise D. Bowman, Ronghua Zhao, Jason E. Hawkes, Ewy A. Mahe, Kensuke Kumamoto, Yiqiang Zhao, Anuradha Budhu, Nobutoshi Hagiwara, Xin Wei Wang, Masao Miyashita, Alan G. Casson, and Curtis C. Harris

Urine Metabolite Analysis Offers Potential Early Diagnosis of Ovarian and Breast Cancers
Carolyn M. Slupsky, Helen Steed, Tiffany H. Wells, Kelly Dabbs, Alexandra Schepansky, Valerie Capstick, Wylam Faught, and Michael B. Sawyer

Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples
Vera L. Costa, Rui Henrique, Stine A. Danielsen, Sara Duarte Pereira, Mette Eknaes, Rolf I. Skotheim, Angelo Rodrigues, José S. Magalhães, Jorge Oliveira, Ragnhild A. Lothe, Manuel R. Teixeira, Carmen Jerónimo, and Guro E. Lind

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors
Michele Del Vecchio, Roberta Montarini, Stefania Canova, Lorenza Di Guardo, Nicola Pimpinelli, Mario R. Settolli, Davide Bedognetti, Paola Queirolo, Paola Morosini, Tania Perrone, Emilio Bajetta, and Andrea Anichini

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Stephanie Heon, Beow Y. Yeap, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, and Bruce E. Johnson

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

Phase 1 First-in-Human Trial of the Vascular disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
Monica M. Mita, Matthew A. Spear, Lorrin K. Yee, Alain C. Mita, Elisabeth I. Heath, Kyriakos P. Papadopoulos, Kristine C. Federico, Steven D. Reich, Ofelia Romero, Lisa Malburg, Marylo Pilat, G. Kenneth Lloyd, Saskia T.C. Neuteboom, Gillian Cropp, Edward Ashton, and Patricia M. LoRusso

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
Ahmad Tarhini, Athanasios Kotsakis, William Gooding, Yongli Shuai, Daniel Petro, David Friedland, Chandra P. Belani, Sanja Dacic, and Athanassios Argiris

Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment

Correction: Systems-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates AIRKRB as a Novel Drug Target for Neuroblastoma

The Journal of Clinical and Translational Research v www.aacrjournals.org
ABOUT THE COVER

Brain metastases of breast cancer are associated with significant morbidity and mortality. In their study, Lockman and colleagues quantified permeability, and paclitaxel and doxorubicin uptake in over 2000 experimental brain metastatic lesions from two model systems. The representative image shown on the cover is a multimodal image illustrating a single metastatic brain lesion which has 10 fold greater permeability compared to that of normal brain. Despite the increased permeability, drug accumulation only reached cytotoxic levels (>1000 ng/g) in a small subset of metastatic lesions, indicating that new brain-permeable drugs will be required. The picture was obtained by multichannel imaging of the eGFP MDA-MB-231Br lesion (green), indocyanine green within the vasculature (yellow), and 14C-AIB phosphorescence (red). For further details, please see Lockman and coworkers on page 5664 in this issue.
Clinical Cancer Research

16 (23)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/23

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.